Achieve Life Sciences Stock (NASDAQ: ACHV)

Achieve Life Sciences Stock (NASDAQ:ACHV), Trade Ideas

Achieve Life Sciences

Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.

Earnings

News

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Intraday Update

Markets

Trading Ideas

ACHV

ADTX

CCCC

ICVX

ORCL

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining over 100 points on Tuesday.

The Dow traded up 0.32% to 36,520.57 while the NASDAQ rose 0.46% to 14,498.23. The S&amp;P 500 also rose, gaining, 0.26% to 4,634.47.

Crude Oil Down 4%; Aditxt Shares Spike Higher

Movers

AAGR

ACLX

ADEX

APPS

BLBD

BRSH

CADL

CAVA

CLIN

CLNE

CMND

EGLE

GSX Techedu Inc. American Depositary Shares

GOTU

GPRO

HCDI

HPCO

HRYU

INAB

IONM

IXHL

KNTK

LCID

NOGN

PAPL

SBOW

SPEC

SVMH

Shares of Johnson Controls International plc (NYSE: JCI) moved lower during Tuesday’s session following weak quarterly results.

Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Biotech

Equities

Health Care

General

Achieve Life Sciences Inc (NASDAQ: ACHV) recently 

Why Is Smoking Cessation-Focused Achieve Life Sciences Stock Trading Lower Today?

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences Inc

JonesTrading analyst Justin Walsh initiates coverage on Achieve Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) with a Buy rating and announces Price Target of $20.

Price Target

Initiation

Analyst Ratings

JonesTrading Initiates Coverage On Achieve Life Sciences with Buy Rating, Announces Price Target of $20

Oppenheimer analyst Francois Brisebois reiterates Achieve Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) with a Outperform and maintains $18 price target.

Reiteration

Oppenheimer Reiterates Outperform on Achieve Life Sciences, Maintains $18 Price Target

Achieve Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) reported its Q4 earnings results on Thursday, March 28, 2024 at 04:01 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Achieve Life Sciences beat estimated earnings by 16.0%, reporting an EPS of $-0.26 versus an estimate of $-0.31.
Revenue was down $0 from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.04 which was followed by a 2.0% drop in the share price the next day.

To track all earnings releases for Achieve Life Sciences <a href="https://www.benzinga.com/quote/ACHV/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Achieve Life Sciences Q4 Earnings

Achieve Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.31) by 16.13 percent. This is a 68.67 percent increase over losses of $(0.83) per share from the same period last year.

Achieve Life Sciences Q4 EPS $(0.26) Beats $(0.31) Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; Universal Stainless (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAP#NASDAQ">USAP</a>) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.
&bull; Shimmick (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIM#NASDAQ">SHIM</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $158.50 million.
&bull; MSC Industrial Direct Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSM#NYSE">MSM</a>) is estimated to report quarterly earnings at $1.16 per share on revenue of $946.55 million.
&bull; Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) is likely to report quarterly earnings at $0.75 per share on revenue of $33.03 billion.
&bull; Data Storage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTST#NASDAQ">DTST</a>) is projected to report earnings for its fourth quarter.
&bull; Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) is likely to report quarterly loss at $1.68 per share on revenue of $1.71 million.
&bull; Atour Lifestyle Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAT#NASDAQ">ATAT</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $168.26 million.
&bull; CNFinance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNF#NYSE">CNF</a>) is likely to report quarterly earnings at $0.01 per share on revenue of $65.41 million.
&bull; BRP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOOO#NASDAQ">DOOO</a>) is estimated to report quarterly earnings at $1.92 per share on revenue of $2.05 billion.
&bull; OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) is estimated to report quarterly earnings at $0.26 per share on revenue of $26.47 million.
&bull; Azul (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) is likely to report quarterly earnings at $0.14 per share on revenue of $985.30 million.
&bull; Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) is projected to report earnings for its fourth quarter.
&bull; Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) is expected to report earnings for its fourth quarter.
&bull; DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) is projected to report quarterly loss at $0.54 per share on revenue of $3.57 million.
&bull; Cheche Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCG#NASDAQ">CCG</a>) is expected to report earnings for its fourth quarter.
&bull; Telesat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSAT#NASDAQ">TSAT</a>) is projected to report earnings for its fourth quarter.
&bull; Jiayin Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>) is projected to report earnings for its fourth quarter.
&bull; IM Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCC#NASDAQ">IMCC</a>) is estimated to report quarterly loss at $0.17 per share on revenue of $10.45 million.
&bull; Smart Share Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EM#NASDAQ">EM</a>) is expected to report earnings for its fourth quarter.
&bull; 36KR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRKR#NASDAQ">KRKR</a>) is projected to report earnings for its fourth quarter.
&bull; 22nd Century Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) is estimated to report quarterly loss at $0.55 per share on revenue of $17.10 million.
&bull; China Automotive Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAAS#NASDAQ">CAAS</a>) is estimated to report earnings for its fourth quarter.
&bull; REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) is expected to report quarterly earnings at $0.68 per share on revenue of $190.26 million.
&bull; D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) is projected to report quarterly loss at $0.10 per share on revenue of $4.73 million.
&bull; Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) is expected to report quarterly loss at $0.25 per share on revenue of $23.66 million.
&bull; American Oncology Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AONC#NASDAQ">AONC</a>) is estimated to report earnings for its fourth quarter.
&bull; Gold Royalty (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GROY#AMEX">GROY</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $1.90 million.
&bull; Better Home &amp; Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BETR#NASDAQ">BETR</a>) is projected to report earnings for its fourth quarter.
&bull; BOS Better Online Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOSC#NASDAQ">BOSC</a>) is projected to report earnings for its fourth quarter.
<h3>Companies Reporting After The Bell</h3>
&bull; INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) is estimated to report quarterly loss at $0.44 per share on revenue of $40 thousand.
&bull; Dolphin Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $11.10 million.
&bull; Ascent Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACNT#NASDAQ">ACNT</a>) is expected to report quarterly loss at $0.08 per share on revenue of $63.50 million.
&bull; Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) is expected to report earnings for its fourth quarter.
&bull; Pineapple Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $20.40 million.
&bull; Oxford Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) is projected to report quarterly earnings at $1.95 per share on revenue of $408.18 million.
&bull; Naas Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) is estimated to report earnings for its fourth quarter.
&bull; Danimer Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNMR#NYSE">DNMR</a>) is projected to report quarterly loss at $0.38 per share on revenue of $11.33 million.
&bull; Dare Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) is expected to report quarterly loss at $0.10 per share on revenue of $1.79 million.
&bull; Intellinetics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INLX#AMEX">INLX</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $4.10 million.
&bull; Shapeways Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPW#NASDAQ">SHPW</a>) is expected to report quarterly loss at $0.95 per share on revenue of $9.25 million.
&bull; NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) is expected to report earnings for its fourth quarter.
&bull; CVD Equipment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVV#NASDAQ">CVV</a>) is projected to report earnings for its fourth quarter.
&bull; Nuvve Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) is expected to report quarterly loss at $5.60 per share on revenue of $3.00 million.
&bull; NexGel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXGL#NASDAQ">NXGL</a>) is projected to report quarterly loss at $0.11 per share on revenue of $1.38 million.
&bull; ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) is expected to report earnings for its fourth quarter.
&bull; Zevra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>) is estimated to report quarterly loss at $0.27 per share on revenue of $11.74 million.
&bull; American Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREC#NASDAQ">AREC</a>) is projected to report quarterly loss at $0.04 per share on revenue of $2.20 million.
&bull; Vicinity Motor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEV#NASDAQ">VEV</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $12.62 million.
&bull; Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) is likely to report quarterly loss at $3.77 per share on revenue of $250 thousand.
&bull; Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) is likely to report quarterly loss at $0.28 per share on revenue of $25.69 million.
&bull; Emeren Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $44.98 million.
&bull; P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) is expected to report quarterly loss at $0.11 per share on revenue of $302.97 million.
&bull; Energous (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) is estimated to report quarterly loss at $0.85 per share on revenue of $200 thousand.
&bull; Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) is likely to report quarterly loss at $0.06 per share on revenue of $800 thousand.
&bull; Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) is projected to report quarterly loss at $0.03 per share on revenue of $196.46 million.
&bull; Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) is likely to report quarterly loss at $0.08 per share on revenue of $274.83 million.
&bull; Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) is likely to report earnings for its fourth quarter.
&bull; Arcadia Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKDA#NASDAQ">RKDA</a>) is projected to report quarterly loss at $2.58 per share on revenue of $1.75 million.
&bull; Achieve Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) is projected to report earnings for its fourth quarter.
&bull; Sharecare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHCR#NASDAQ">SHCR</a>) is expected to report quarterly loss at $0.06 per share on revenue of $114.99 million.
&bull; Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) is projected to report quarterly loss at $0.28 per share on revenue of $980 thousand.
&bull; Cepton (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPTN#NASDAQ">CPTN</a>) is expected to report quarterly loss at $0.74 per share on revenue of $2.46 million.
&bull; Vuzix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VUZI#NASDAQ">VUZI</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $2.14 million.
&bull; Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) is estimated to report quarterly loss at $0.45 per share on revenue of $2.54 million.
&bull; Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) is estimated to report quarterly loss at $0.03 per share on revenue of $5.56 million.
&bull; Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) is estimated to report quarterly loss at $0.62 per share on revenue of $3.45 million.
&bull; Wrap Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRAP#NASDAQ">WRAP</a>) is likely to report earnings for its fourth quarter.
&bull; Planet Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) is projected to report quarterly loss at $0.06 per share on revenue of $58.19 million.
&bull; Leafly Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFLY#NASDAQ">LFLY</a>) is likely to report quarterly loss at $1.45 per share on revenue of $9.49 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ACNT

AFMD

AONC

AREC

ATAT

AXDX

AZUL

BETR

BOSC

CAAS

CPTN

CURV

DARE

DLPN

DNMR

DOOO

DRIO

DTST

DYAI

FORA

GROY

HSDT

IMCC

IMNN

INLX

INMB

ITRM

JFIN

KRKR

LFLY

NAAS

NDRA

NRXP

NVVE

NXGL

OPRX

PEGY

PIII

PLSE

QBTS

RKDA

SHCR

SHIM

SHPW

SMTC

SRFM

TSAT

USAP

VUZI

WATT

WRAP

XPON

XXII

ZVRA

Earnings Scheduled For March 28, 2024

Achieve Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) is set to give its latest quarterly earnings report on Thursday, 2024-03-28. Here's what investors need to know before the announcement.
Analysts estimate that Achieve Life Sciences will report an earnings per share (EPS) of $-0.31. 
Achieve Life Sciences bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.04, which was followed by a 1.91% drop in the share price the next day.
Here's a look at Achieve Life Sciences's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.38</td>
<td>-0.42</td>
<td>-0.69</td>
<td>-0.83</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.34</td>
<td>-0.43</td>
<td>-0.50</td>
<td>-0.83</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>-3.0%</td>
<td>13.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1711551724_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Achieve Life Sciences were trading at $4.66 as of March 26. Over the last 52-week period, shares are down 27.85%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/ACHV/earnings">To track all earnings releases for Achieve Life Sciences visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Achieve Life Sciences's Earnings: A Preview

Events

Achieve Life Sciences Announces Data From Cytisinicline ORCA Program To Be Presented At 2024 Society For Research On Nicotine And Tobacco Annual Meeting

Franklin Resources Reports 12.0% Passive Stake In Achieve Life Sciences Inc As Of February 29, 2024

Lake Street analyst Thomas Flaten maintains Achieve Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) with a Buy and lowers the price target from $19 to $11.

Lake Street Maintains Buy on Achieve Life Sciences, Lowers Price Target to $11

Offerings

Achieve Life Sciences Announces Pricing Of $124.2M Registered Direct Offering Of 13,086,151 Shares At $4.585/Share; Concurrent Private Placement Company To Issue Unregistered Warrants To Purchase 13,086,151 Shares At $4.906/Share

Achieve Life Sciences Reaches Agreement With FDA On Long-Term Cytisinicline Exposure Data Requirements For NDA Submission

WIIM

Achieve Life Sciences shares are trading lower after the company announced that New Drug Application filing timing may be delayed to address FDA feedback on Cytisinicline. Also, Oppenheimer lowered its price target from $21 to $18 on the stock.

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining over 100 points on Tuesday.
The Dow traded up 0.32% to 36,520.57 while the NASDAQ rose 0.46% to 14,498.23. The S&amp;P 500 also rose, gaining, 0.26% to 4,634.47.
Check This Out: <a href="https://www.benzinga.com/news/23/12/36192758/microsoft-u-s-bancorp-and-2-other-stocks-insiders-are-selling"> Microsoft, U.S. Bancorp And 2 Other Stocks Insiders Are Selling</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Materials shares rose by 0.5% on Tuesday.
In trading on Tuesday, energy shares fell by 1.7%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Johnson Controls International plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jci#NYSE">JCI</a>) reported weak results for its fourth quarter.
Johnson Controls reported fourth-quarter FY23 sales growth of 2.7% year-on-year to $6.91 billion (+2% organically), missing the consensus of $7.09 billion. Adjusted EPS of $1.05 (+6% Y/Y) below the consensus of $1.09, according to Benzinga Pro.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Aditxt, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adtx#NASDAQ">ADTX</a>) shares shot up 64% to $6.25. Aditxt agreed to acquire Evofem Biosciences in consideration of the issuance of a combination of common stock and preferred stock and the assumption of certain senior indebtedness, having an aggregate amount of approximately $100 million.
Shares of C4 Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cccc#NASDAQ">CCCC</a>) got a boost, surging 108% to $2.45. C4 Therapeutics entered into an exclusive license and collaboration agreement with Merck &amp; Co to develop degrader-antibody conjugates (DACs), an emerging modality designed to selectively target and neutralize disease-causing proteins in cancer cells.
Icosavax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icvx#NASDAQ">ICVX</a>) shares were also up, gaining 48% to $15.49. AstraZeneca agreed to acquire Icosavax at $15.00 per share in cash at closing, plus a non-tradable contingent value right to receive up to $5.00 in cash, payable upon achievement of specified regulatory and net sales milestones.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Achieve Life Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/achv#NASDAQ">ACHV</a>) shares dropped 42% to $3.1350. Achieve Life Sciences said NDA Filing timing may be delayed to address FDA feedback on drug product candidate, Cytisinicline. Oppenheimer maintained Achieve Life Sciences with an Outperform and lowered the price target from $21 to $18.
Shares of Oracle Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/orcl#NYSE">ORCL</a>) were down 12% to $101.50. Oracle reported upbeat earnings for its second quarter, while sales missed estimates.
Green Giant Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gge#NASDAQ">GGE</a>) was down, falling 44% to $0.0850 as the company announced pricing of public offering.
Also Check This Out:<a href="https://www.benzinga.com/news/23/12/36196130/dont-miss-these-3-high-yielding-dividend-stocks-in-health-care-sector-from-wall-streets-most-accurat"> Don&#39;t Miss These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street&#39;s Most Accurate Analysts</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 4.1% to $68.37 while gold traded up 0.1% at $1,994.70.
Silver traded down 0.1% to $23.045 on Tuesday while copper rose 0.2% to $3.7880.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares closed lower today. The eurozone&rsquo;s STOXX 600 fell 0.21%, London&rsquo;s FTSE 100 fell 0.03% while Spain&rsquo;s IBEX 35 Index fell 0.78% The German DAX fell 0.02% French CAC 40 fell 0.11%, while Italy&rsquo;s FTSE MIB Index fell 0.28%.
The ZEW Indicator of Economic Sentiment for the Eurozone surged by 9.2 points to 23 in December, recording the strongest reading in ten months, while German ZEW Indicator of Economic Sentiment rose to 12.8 in December from 9.8 in November.
The number of job vacancies in the UK fell to 949,000 from September to November, while regular pay, excluding bonus payment in the UK, rose 7.3% year-over-year to GBP 620/week in the three months to October.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mostly higher on Tuesday, with Japan&rsquo;s Nikkei 225 gaining 0.16%, Hong Kong&rsquo;s Hang Seng Index gaining 1.07% and China&rsquo;s Shanghai Composite Index gaining 0.40%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, fell 0.54%.
Producer prices in Japan increased 0.3% year-over-year in November following a revised 0.9% rise in October.
&nbsp;
<h3>Economics</h3>
&nbsp;
The NFIB Small Business Optimism Index declined for a fourth straight month to a reading of 90.6 in November.
The annual inflation rate in the U.S. eased to 3.1% in November, recording the lowest reading in five months, compared to 3.2% in October.
Now Read This: <a href="https://www.benzinga.com/news/23/12/36195518/top-5-utilities-stocks-that-should-keep-you-up-at-night"> Top 5 Utilities Stocks That Should Keep You Up At Night</a>

Shares of Johnson Controls International plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jci#NYSE">JCI</a>) moved lower during Tuesday&rsquo;s session following <a href="https://www.benzinga.com/news/earnings/23/12/36196285/building-solutions-provider-johnson-controls-q4-results-fall-short-of-expectations-details">weak quarterly results.</a>
Johnson Controls reported fourth-quarter FY23 sales growth of 2.7% year-on-year to $6.91 billion (+2% organically), missing the consensus of $7.09 billion. Adjusted EPS of $1.05 (+6% Y/Y) below the consensus of $1.09, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Johnson Controls International shares fell 6.2% to $53.05 on Tuesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Aditxt, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adtx#NASDAQ">ADTX</a>) shares jumped 140.5% to $9.14 after the company entered into definitive agreement to acquire Evofem Biosciences.</li>
<li>C4 Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cccc#NASDAQ">CCCC</a>) gained 57.5% to $1.8590 after the company announced a license and research collaboration with Merck to discover and develop degrader-antibody conjugates.</li>
<li>Candel Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cadl#NASDAQ">CADL</a>) shares climbed 48% to $1.24 after the company announced it received FDA Fast Track Designation for CAN-2409 in pancreatic cancer.</li>
<li>Icosavax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icvx#NASDAQ">ICVX</a>) rose climbed 47.1% to $15.43 after AstraZeneca announced plans to buy Icosavax in a deal valued at up to $1.1 billion. Concurrently, Icosavax released topline interim results for its Phase 2 study of IVX-A12, a combination virus-like particle (VLP) vaccine candidate targeting both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).</li>
<li>Clean Earth Acquisitions Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clin#NASDAQ">CLIN</a>) gained 41.3% to $6.71. Clean Earth and Alternus Energy announced continuation of business combination close process.</li>
<li>Bruush Oral Care Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brsh#NASDAQ">BRSH</a>) shares rose 24.1% to $0.2022 after gaining over 5% on Monday.</li>
<li>Spectaire Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spec#NASDAQ">SPEC</a>) gained 23.7% to $2.1286. Spectaire announced manufacturing financing agreement to enable mass production.</li>
<li>Gaotu Techedu Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gotu#NYSE">GOTU</a>) rose 18% to $3.4650.</li>
<li>IN8bio, Inc.(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inab#NASDAQ">INAB</a>) gained 17.8% to $1.5080 after the company announced updated data from its Phase 1 investigator-sponsored trial of INB-100 in patients with hematologic malignancies.</li>
<li>Pineapple Financial Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/papl#NYSE">PAPL</a>) rose 13.9% to $2.29.</li>
<li>Intchains Group Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/icg#NYSE">ICG</a>) gained 13.5% to $10.16.</li>
<li>Oil-Dri Corporation of America (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/odc#NYSE">ODC</a>) rose 12.2% to $66.09 following first-quarter results.</li>
<li>Hanryu Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hryu#NASDAQ">HRYU</a>) shares surged 11.2% to $0.70 after jumping 40% on Monday.</li>
<li>CAVA Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cava#NYSE">CAVA</a>) gained 9.8% to $35.68.</li>
<li>Eagle Bulk Shipping Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/egle#NYSE">EGLE</a>) jumped 9.2% to $50.42. Star Bulk and Eagle Bulk Shipping announced plans to combine.</li>
<li>Blue Bird Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blbd#NASDAQ">BLBD</a>) shares rose 9.1% to $23.80 after the company reported better-than-expected financial results for its fourth quarter and increased its FY24 revenue forecast.</li>
<li>Digital Turbine, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apps#NASDAQ">APPS</a>) gained 7.8% to $6.58.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Achieve Life Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/achv#NASDAQ">ACHV</a>) shares fell 41.9% to $3.1686. Achieve Life Sciences said NDA Filing timing may be delayed to address FDA feedback on drug product candidate, Cytisinicline. Oppenheimer maintained Achieve Life Sciences with an Outperform and lowered the price target from $21 to $18.</li>
<li>Boqii Holding Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bq#NYSE">BQ</a>) fell 37.7% to $1.3824.</li>
<li>Green Giant Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gge#NASDAQ">GGE</a>) declined 36.7% to $0.0962 as the company announced pricing of public offering.</li>
<li>SRIVARU Holding Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/svmh#NASDAQ">SVMH</a>) fell 30.3% to $0.4999 after jumping 20% on Monday.</li>
<li>Harbor Custom Development, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hcdi#NASDAQ">HCDI</a>) fell 26.8% to $0.4975. Harbor Custom Development voluntarily filed for protection under Chapter 11 Bankruptcy.</li>
<li>Assure Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ionm#NASDAQ">IONM</a>) shares fell 26% to $0.32 after climbing over 23% on Monday.</li>
<li>African Agriculture Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aagr#NASDAQ">AAGR</a>) declined 20% to $0.8747.</li>
<li>Adit EdTech Acquisition Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/adex#NYSE">ADEX</a>) fell 17.7% to $6.05.</li>
<li>Nogin, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nogn#NASDAQ">NOGN</a>) fell 17.5% to $0.1402.</li>
<li>Bon Natural Life Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bon#NASDAQ">BON</a>) fell 17.1% to $0.4974.</li>
<li>Incannex Healthcare Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ixhl#NASDAQ">IXHL</a>) declined 11.2% to $4.4201.</li>
<li>Hempacco Co., Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hpco#NASDAQ">HPCO</a>) shares fell 11.1% to $0.3598.</li>
<li>Oracle Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/orcl#NYSE">ORCL</a>) fell 10.3% to $103.32. Oracle reported upbeat earnings for its second quarter, while sales missed estimates.</li>
<li>Clean Energy Fuels Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clne#NASDAQ">CLNE</a>) dipped 10.1% to $3.2550.</li>
<li>Clearmind Medicine Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmnd#NASDAQ">CMND</a>) fell 9.1% to $2.7650. Clearmind Medicine filed for mixed shelf of up to $50 million.</li>
<li>Lucid Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lcid#NASDAQ">LCID</a>) shares fell 8.8% to $4.2050. Lucid Group disclosed that CFO Sherry House is resigning to pursue other opportunities.</li>
<li>Arcellx, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aclx#NASDAQ">ACLX</a>) fell 8.7% to $47.79. Needham reiterated Arcellx with a Buy and maintained a $65 price target.</li>
<li>GoPro, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gpro#NASDAQ">GPRO</a>) declined 8.4% to $3.28. Morgan Stanley downgraded GoPro from Equal-Weight to Underweight and lowered the price target from $4 to $3.</li>
<li>SilverBow Resources, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sbow#NYSE">SBOW</a>) dipped 7.7% to $27.65. SilverBow Resources announced the upsize and pricing of a previously announced underwritten public offering of its common by an affiliate of Strategic Value Partners, LLC.</li>
<li>Kinetik Holdings Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kntk#NYSE">KNTK</a>) shares fell 3.4% to $33.17. Kinetik reported the pricing of an upsized underwritten secondary offering of 6,500,000 shares of its Class A common stock by Apache Midstream LLC at a price of $31.50 per share.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/23/12/36196130/dont-miss-these-3-high-yielding-dividend-stocks-in-health-care-sector-from-wall-streets-most-accurat"> Don&#39;t Miss These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street&#39;s Most Accurate Analysts</a>
&nbsp;

Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Achieve Life Sciences Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/achv#NASDAQ">ACHV</a>) recently&nbsp;<a class="editor-rtfLink" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/949858/000095017023069392/achv-20231211.htm" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">conducted</a>&nbsp;a pre-New Drug Application (NDA) meeting with the FDA for the company&rsquo;s drug&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/23/05/32531563/cant-kick-the-bud-achieves-cytisinicline-proves-promising-in-phase-3-smoking-cessation-trial" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">product candidate, cytisinicline</a>.
During that meeting, the FDA supported an NDA submission based on adequate data to assess efficacy from the two randomized and controlled Phase 3 trials.&nbsp;
In addition, the FDA advised that long-term exposure data beyond 12 weeks would be needed to adequately assess safety risk, given that it views smoking cessation drugs as products for chronic, intermittent use because patients may relapse and require subsequent courses of treatment over a lifetime.&nbsp;
The FDA advised that long-term safety data could be collected on a patient&rsquo;s cumulative treatment over time and could also be collected in the vaping cessation program.&nbsp;
The company is participating in ongoing discussions with the FDA to clarify the requirements and timing for the long-term exposure safety data to support an NDA submission.&nbsp;
The company&rsquo;s NDA filing timing may be delayed to address this FDA feedback.&nbsp;
Following receipt of additional input from the FDA, anticipated in Q1 of 2024, the company will provide an update on its projected NDA submission timing.&nbsp;
Price Action:&nbsp;ACHV shares are down 41.6% at $3.18 on the last check Tuesday.

<h3>Gainers</h3>
<ul>
<li>C4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCCC#NASDAQ">CCCC</a>) stock increased by 100.5% to $2.37 during Tuesday's regular session. The market value of their outstanding shares is at $116.6 million. </li>
<li>Aditxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) shares rose 68.94% to $6.42. The market value of their outstanding shares is at $2.8 million. </li>
<li>Icosavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICVX#NASDAQ">ICVX</a>) shares rose 48.61% to $15.59. The company's market cap stands at $780.9 million. </li>
<li>Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) shares moved upwards by 32.98% to $1.16. The company's market cap stands at $33.4 million. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) shares increased by 29.93% to $1.66. The market value of their outstanding shares is at $53.2 million. </li>
<li>PAVmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAVM#NASDAQ">PAVM</a>) stock rose 29.33% to $4.01. The market value of their outstanding shares is at $32.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLDO#NASDAQ">CCLDO</a>) stock declined by 68.4% to $4.36 during Tuesday's regular session. </li>
<li>CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLDP#NASDAQ">CCLDP</a>) stock fell 66.43% to $5.12. </li>
<li>Achieve Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) stock fell 41.47% to $3.19. The company's market cap stands at $67.5 million. </li>
<li>Eterna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) stock fell 23.46% to $1.2. The market value of their outstanding shares is at $6.4 million. </li>
<li>CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>) stock declined by 21.57% to $0.8. The market value of their outstanding shares is at $12.6 million. </li>
<li>Vapotherm (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAPO#NYSE">VAPO</a>) stock decreased by 20.01% to $1.2. The market value of their outstanding shares is at $7.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CCLD

CCLDO

CCLDP

ERNA

PAVM

VAPO

12 Health Care Stocks Moving In Tuesday's Intraday Session

U.S. stocks turned higher midway through trading, with the Dow Jones index gaining more than 100 points on Tuesday.
The Dow traded up 0.35% to 36,533.63 while the NASDAQ rose 0.16% to 14,455.15 The S&amp;P 500 also rose, gaining, 0.10% to 4,627.04
Check This Out: <a href="https://www.benzinga.com/news/23/12/36192758/microsoft-u-s-bancorp-and-2-other-stocks-insiders-are-selling"> Microsoft, U.S. Bancorp And 2 Other Stocks Insiders Are Selling</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Industrials shares rose by 0.3% on Tuesday.
In trading on Tuesday, energy shares fell by 1%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Oracle Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/orcl#NYSE">ORCL</a>) reported upbeat earnings for its second quarter, while sales missed estimates.
Oracle reported quarterly adjusted earnings of $1.34 per share, topping the Street&#39;s estimate of $1.32. Revenue of $12.94 billion fell short of the analyst consensus estimate of $13.05 billion.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Aditxt, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adtx#NASDAQ">ADTX</a>) shares shot up 78% to $6.76. Aditxt agreed to acquire Evofem Biosciences in consideration of the issuance of a combination of common stock and preferred stock and the assumption of certain senior indebtedness, having an aggregate amount of approximately $100 million.
Shares of C4 Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cccc#NASDAQ">CCCC</a>) got a boost, surging 93% to $2.28. C4 Therapeutics entered into an exclusive license and collaboration agreement with Merck &amp; Co to develop degrader-antibody conjugates (DACs), an emerging modality designed to selectively target and neutralize disease-causing proteins in cancer cells.
Icosavax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icvx#NASDAQ">ICVX</a>) shares were also up, gaining 48% to $15.51. AstraZeneca agreed to acquire Icosavax at $15.00 per share in cash at closing, plus a non-tradable contingent value right to receive up to $5.00 in cash, payable upon achievement of specified regulatory and net sales milestones.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Achieve Life Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/achv#NASDAQ">ACHV</a>) shares dropped 40% to $3.2697. Achieve Life Sciences said NDA Filing timing may be delayed to address FDA feedback on drug product candidate, Cytisinicline. Oppenheimer maintained Achieve Life Sciences with an Outperform and lowered the price target from $21 to $18.
Shares of Harbor Custom Development, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hcdi#NASDAQ">HCDI</a>) were down 26% to $0.5015. Harbor Custom Development voluntarily filed for protection under Chapter 11 Bankruptcy.
Green Giant Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gge#NASDAQ">GGE</a>) was down, falling 40% to $0.0913 as the company announced pricing of public offering.
Also Check This Out:<a href="https://www.benzinga.com/news/23/12/36196130/dont-miss-these-3-high-yielding-dividend-stocks-in-health-care-sector-from-wall-streets-most-accurat"> Don&#39;t Miss These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street&#39;s Most Accurate Analysts</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 2.5% to $69.52 while gold traded up 0.2% at $1,998.50.
Silver traded up 0.3% to $23.13 on Tuesday while copper rose 0.1% to $3.7850.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mixed today. The eurozone&rsquo;s STOXX 600 fell 0.21%, London&rsquo;s FTSE 100 rose 0.02% while Spain&rsquo;s IBEX 35 Index fell 0.63% The German DAX rose 0.01% French CAC 40 rose 0.06%, while Italy&rsquo;s FTSE MIB Index fell 0.07%.
The ZEW Indicator of Economic Sentiment for the Eurozone surged by 9.2 points to 23 in December, recording the strongest reading in ten months, while German ZEW Indicator of Economic Sentiment rose to 12.8 in December from 9.8 in November.
The number of job vacancies in the UK fell to 949,000 from September to November, while regular pay, excluding bonus payment in the UK, rose 7.3% year-over-year to GBP 620/week in the three months to October.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mostly higher on Tuesday, with Japan&rsquo;s Nikkei 225 gaining 0.16%, Hong Kong&rsquo;s Hang Seng Index gaining 1.07% and China&rsquo;s Shanghai Composite Index gaining 0.40%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, fell 0.54%.
Producer prices in Japan increased 0.3% year-over-year in November following a revised 0.9% rise in October.
&nbsp;
<h3>Economics</h3>
&nbsp;
The NFIB Small Business Optimism Index declined for a fourth straight month to a reading of 90.6 in November.
The annual inflation rate in the U.S. eased to 3.1% in November, recording the lowest reading in five months, compared to 3.2% in October.
Now Read This: <a href="https://www.benzinga.com/news/23/12/36195518/top-5-utilities-stocks-that-should-keep-you-up-at-night"> Top 5 Utilities Stocks That Should Keep You Up At Night</a>

Dow Jumps Over 100 Points; Oracle Posts Mixed Q2 Results

U.S. stocks traded slightly lower this morning, following the release of inflation data on Tuesday.
Following the market opening Tuesday, the Dow traded down 0.04% to 36,389.01 while the NASDAQ fell 0.18% to 14,406.14. The S&amp;P 500 also fell, dropping, 0.27% to 4,610.13.
Check This Out: <a href="https://www.benzinga.com/news/23/12/36192758/microsoft-u-s-bancorp-and-2-other-stocks-insiders-are-selling"> Microsoft, U.S. Bancorp And 2 Other Stocks Insiders Are Selling</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Industrials shares rose by 0.8% on Tuesday.
In trading on Tuesday, communication services shares fell by 1.5%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
The annual inflation rate in the U.S. eased to 3.1% in November, recording the lowest reading in five months, compared to 3.2% in October.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Aditxt, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adtx#NASDAQ">ADTX</a>) shares shot up 103% to $7.70 after the company entered into definitive agreement to acquire Evofem Biosciences.
Shares of C4 Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cccc#NASDAQ">CCCC</a>) got a boost, surging 56% to $1.8350 after the company announced a license and research collaboration with Merck to discover and develop degrader-antibody conjugates.
Candel Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cadl#NASDAQ">CADL</a>) shares were also up, gaining 58% to $1.32 after the company announced it received FDA Fast Track Designation for CAN-2409 in pancreatic cancer.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Achieve Life Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/achv#NASDAQ">ACHV</a>) shares dropped 39% to $3.33. Achieve Life Sciences said NDA Filing timing may be delayed to address FDA feedback on drug product candidate, Cytisinicline. Oppenheimer maintained Achieve Life Sciences with an Outperform and lowered the price target from $21 to $18.
Shares of Harbor Custom Development, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hcdi#NASDAQ">HCDI</a>) were down 40% to $0.4102. Harbor Custom Development voluntarily filed for protection under Chapter 11 Bankruptcy.
Assure Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ionm#NASDAQ">IONM</a>) was down, falling 28% to $0.3100 after climbing over 23% on Monday.
Also Check This Out:<a href="https://www.benzinga.com/news/23/12/36196130/dont-miss-these-3-high-yielding-dividend-stocks-in-health-care-sector-from-wall-streets-most-accurat"> Don&#39;t Miss These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street&#39;s Most Accurate Analysts</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 2.6% to $69.45 while gold traded up 0.4% at $2,001.30.
Silver traded up 0.7% to $23.22 on Tuesday while copper rose 0.3% to $3.7915.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mixed today. The eurozone&rsquo;s STOXX 600 fell 0.2%, London&rsquo;s FTSE 100 rose 0.1% while Spain&rsquo;s IBEX 35 Index fell 0.8% The German DAX fell 0.1% French CAC 40 rose 0.1%, while Italy&rsquo;s FTSE MIB Index fell 0.1%.
The ZEW Indicator of Economic Sentiment for the Eurozone surged by 9.2 points to 23 in December, recording the strongest reading in ten months, while German ZEW Indicator of Economic Sentiment rose to 12.8 in December from 9.8 in November.
The number of job vacancies in the UK fell to 949,000 from September to November, while regular pay, excluding bonus payment in the UK, rose 7.3% year-over-year to GBP 620/week in the three months to October.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mostly higher on Tuesday, with Japan&rsquo;s Nikkei 225 gaining 0.16%, Hong Kong&rsquo;s Hang Seng Index gaining 1.07% and China&rsquo;s Shanghai Composite Index gaining 0.40%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, fell 0.54%.
Producer prices in Japan increased 0.3% year-over-year in November following a revised 0.9% rise in October.
&nbsp;
<h3>Economics</h3>
&nbsp;
The annual inflation rate in the U.S. eased to 3.1% in November, recording the lowest reading in five months, compared to 3.2% in October.
Now Read This: <a href="https://www.benzinga.com/news/23/12/36195518/top-5-utilities-stocks-that-should-keep-you-up-at-night"> Top 5 Utilities Stocks That Should Keep You Up At Night</a>

US Stocks Edge Lower; Inflation Rate Slows to 3.1% In November

<h3>Gainers</h3>
<ul>
<li>C4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCCC#NASDAQ">CCCC</a>) stock rose 59.7% to $1.89 during Tuesday's pre-market session. The company's market cap stands at $92.8 million. </li>
<li>Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) stock increased by 47.38% to $1.28. The company's market cap stands at $37.0 million. </li>
<li>Icosavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICVX#NASDAQ">ICVX</a>) shares increased by 45.85% to $15.3. The market value of their outstanding shares is at $766.3 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) stock moved upwards by 33.07% to $8.65. The market value of their outstanding shares is at $321.4 million. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) stock rose 28.12% to $1.64. The company's market cap stands at $52.4 million. </li>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) stock rose 23.06% to $0.21. The market value of their outstanding shares is at $2.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLDP#NASDAQ">CCLDP</a>) shares declined by 35.9% to $9.77 during Tuesday's pre-market session. </li>
<li>Achieve Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) stock decreased by 26.61% to $4.0. The market value of their outstanding shares is at $84.6 million. </li>
<li>Assure Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONM#NASDAQ">IONM</a>) shares fell 24.4% to $0.33. The company's market cap stands at $2.1 million. </li>
<li>Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) stock declined by 15.68% to $0.37. The market value of their outstanding shares is at $7.7 million. </li>
<li>CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLDO#NASDAQ">CCLDO</a>) stock decreased by 15.02% to $11.74. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) stock decreased by 11.98% to $0.46. The market value of their outstanding shares is at $3.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEON

KTTA

SNOA

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>BTIG raised Velocity Financial, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vel#NYSE">VEL</a>) price target from $14 to $17. BTIG analyst Sarah Barcomb maintained a Buy rating. Velocity Financial shares gained 2% to close at $15.00 on Monday. <a href="https://www.benzinga.com/quote/VEL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup boosted the price target for Adobe Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adbe#NASDAQ">ADBE</a>) from $610 to $675. Citigroup analyst Tyler Radke maintained a Neutral rating. Adobe shares rose 2.5% to close at $625.20 on Monday. <a href="https://www.benzinga.com/quote/ADBE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer cut the price target for Achieve Life Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/achv#NASDAQ">ACHV</a>) from $21 to $18. Oppenheimer analyst Francois Brisebois maintained an Outperform rating. Achieve Life Sciences shares fell 1.1% to close at $5.45 on Monday. <a href="https://www.benzinga.com/quote/ACHV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham boosted the price target for Semrush Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/semr#NYSE">SEMR</a>) from $13 to $15. Needham analyst Scott Berg maintained a Buy rating. Semrush shares fell 0.3% to close at $11.47 on Monday. <a href="https://www.benzinga.com/quote/SEMR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays cut the price target for Airbnb, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abnb#NASDAQ">ABNB</a>) from $135 to $100. Barclays analyst Mario Lu downgraded the stock from Equal-Weight to Underweight. Airbnb shares gained 1.6% to close at $142.91 on Monday. <a href="https://www.benzinga.com/quote/ABNB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>RBC Capital increased Amgen Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amgn#NASDAQ">AMGN</a>) price target from $256 to $300. RBC Capital analyst Gregory Renza upgraded the stock from Sector Perform to Outperform. Amgen shares gained 1.1% to close at $272.14 on Monday. <a href="https://www.benzinga.com/quote/AMGN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley slashed GoPro, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gpro#NASDAQ">GPRO</a>) price target from $4 to $3. Morgan Stanley analyst Erik Woodring downgraded the stock from Equal-Weight to Underweight. GoPro shares gained 0.9% to close at $3.58 on Monday. <a href="https://www.benzinga.com/quote/GPRO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley boosted HP Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hpq#NYSE">HPQ</a>) price target from $31 to $35. Morgan Stanley analyst Erik Woodring upgraded the stock from Equal-Weight to Overweight. HP shares rose 3.1% to close at $30.37 on Monday. <a href="https://www.benzinga.com/quote/HPQ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler cut Oracle Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/orcl#NYSE">ORCL</a>) price target from $130 to $125. Piper Sandler analyst Brent Bracelin maintained an Overweight rating. Oracle shares rose 1.3% to close at $115.13 on Monday. <a href="https://www.benzinga.com/quote/ORCL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group boosted PVH Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pvh#NYSE">PVH</a>) price target from $111 to $122. Telsey Advisory Group analyst Dana Telsey maintained an Outperform rating. PVH shares rose 2.1% to close at $110.49 on Monday. <a href="https://www.benzinga.com/quote/PVH/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/news/23/12/36191468/oracle-reports-weak-sales-joins-kinetik-lucid-group-and-other-big-stocks-moving-lower-in-tuesdays-pr"> Oracle Reports Weak Sales, Joins Kinetik, Lucid Group And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session </a>

ABNB

ADBE

AMGN

SEMR

PVH To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday

Notable earnings after Thursday's close

Today, several major companies are expected to report earnings: Achieve Life Sciences (ACHV), Emeren Group (SOL), Semtech (SMTC), Walgreens Boots A...

Options Volatility and Implied Earnings Moves Today, March 28, 2024

Achieve Life Sciences GAAP EPS of -$0.26 beats by $0.05

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Achieve Life Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/achv-stock-quote/">ACHV</a>) just reported results for the fourth quarter of 2023.<ul><li>Achieve Life Sciences reported earnings per share of -26 cents. This was above the analyst estimate for EPS of -31 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/achv-stock-earnings-achieve-life-sciences-for-q4-of-2023/">ACHV Stock Earnings: Achieve Life Sciences Beats EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ACHV Stock Earnings: Achieve Life Sciences Beats EPS for Q4 2023

Achieve Life Sciences, Inc. (ACHV) Q4 2023 Earnings Call Transcript

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Achieve Life Sciences (ACHV – Research Report) and P...

Analysts Offer Insights on Healthcare Companies: Achieve Life Sciences (ACHV) and Phathom Pharmaceuticals (PHAT)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Forian (FORA – Research Report), Achieve Life Scienc...

Analysts Offer Insights on Healthcare Companies: Forian (FORA), Achieve Life Sciences (ACHV) and P3 Health Partners (PIII)

Achieve Life Sciences: An Excellent Drug Addressing A Large Market Could Drive 5x Returns

Achieve Life Sciences (ACHV) has received a new Buy rating, initiated by JonesTrading analyst, Justin Walsh. Justin Walsh has given his Buy rating ...

Achieve Life Sciences: A Strong Buy for Tobacco Cessation Market Penetration

Jones starts Achieve Life Sciences at buy, cites market opportunity

GDNSF

PHAT

REED

Press Releases

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

Opinion

Thinking about buying stock in Advanced Micro Devices, Palo Alto Networks, Gaotu Techedu, Achieve Life Sciences, or Clearmind Medicine?

Management

TFF Pharmaceuticals Appoints Thomas B. King to Board of Directors

Financing

Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement

Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call and Webcast on March 28, 2024

Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update

Achieve Life Sciences to Present at Life Science Innovation Northwest 2024 Conference

PANW

TFFP

Adicet Bio